Samina Hamied, 48, third generation heir to Cipla, founded in 1935 by her grandfather Khwaja Abdul Hamied, challenges herself ...

Ethris reported initial positive Phase I data for its intranasal mRNA vaccine candidate, ETH47. "Ethris and Lonza to develop mRNA vaccines for respiratory conditions ...

MUNICH, Germany & BASEL, Switzerland I April 07, 2025 I Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest ...

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world's largest contract development and manufacturing organizations ...

Under the terms of the agreement, Lonza will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM® RNA) and stabilized ...

Formulations to be developed at Lonza’s Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US), in accordance with current Good Manufacturing Practice (cGMP) standards ...

Ethris and Lonza agreed to collaborate on the development of room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory ...

German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza (SWX: LONN), have announced a collaboration. The deal is ...

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based ...

The mRNA Cancer Vaccines and Therapeutics Market has emerged as one of the most promising sectors within the biotechnology and oncology landscape. mRNA, or messenger RNA, serves as a genetic blueprint ...